Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Debt (2020 - 2024)

Historic Total Debt for Syndax Pharmaceuticals (SNDX) over the last 5 years, with Q4 2024 value amounting to $343.7 million.

  • Syndax Pharmaceuticals' Total Debt changed N/A to $343.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $343.7 million, marking a year-over-year change of. This contributed to the annual value of $343.7 million for FY2024, which is N/A changed from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Total Debt stood at $343.7 million for Q4 2024.
  • Over the past 5 years, Syndax Pharmaceuticals' Total Debt peaked at $343.7 million during Q4 2024, and registered a low of $19.8 million during Q1 2020.
  • In the last 4 years, Syndax Pharmaceuticals' Total Debt had a median value of $20.1 million in 2020 and averaged $49.5 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Total Debt skyrocketed by 235.93% in 2021, and later plummeted by 92.42% in 2022.
  • Syndax Pharmaceuticals' Total Debt (Quarter) stood at $20.1 million in 2020, then dropped by 0.18% to $20.1 million in 2021, then grew by 0.62% to $20.2 million in 2022, then soared by 1600.89% to $343.7 million in 2024.
  • Its Total Debt stands at $343.7 million for Q4 2024, versus $20.2 million for Q2 2022 and $20.0 million for Q1 2022.